Hyperammonemia Causes and Mechanisms

Primary Causes

• Congenital deficiency of any of the six enzymes in the urea cycle, including N-acetylglutamate synthase (NAGS) deficiency, Carbamoyl phosphate synthase I (CPS) deficiency, Ornithine transcarbamylase (OTC) deficiency, Argininosuccinate synthetase (ASS) deficiency, Argininosuccinate lyase (ASL) deficiency, and Arginase 1 deficiency, leads to ammonia accumulation 1, 2
• Ornithine transcarbamylase (OTC) deficiency is the most common UCD with an incidence of 1 in 56,500 births 3, 2

Secondary Causes

• Organic acidemias, such as Methylmalonic acidemia, Isovaleric acidemia, and Multiple carboxylase deficiency, occur in approximately 1 in 21,000 births and can lead to hyperammonemia 3, 1, 3, 4
• Valproic acid (Depakene) can inhibit the urea cycle and lead to hyperammonemia 3, 4
• Acute kidney injury can impair ammonia excretion 3, 4

Physiological Mechanisms

• Ammonia is produced through amino acid catabolism, activity of glutamine dehydrogenase in liver, kidney, pancreas, and brain, deamination of AMP during exercise, and bacterial splitting of urea in the intestines 2
• Normal ammonia processing involves the urea cycle in hepatocytes, conversion to urea for urinary excretion, and conversion to glutamine, partially excreted by kidneys 2, 1

Clinical Significance

• Normal blood ammonia concentrations are ≤35 μmol/L (≤60 μg/dL) 2, 4
• Hyperammonemia is defined as >100 μmol/L (170 μg/dL) in neonates, ≥50 μmol/L (85 μg/dL) in term infants, children, and adults 3, 2, 4
• Levels >200 μmol/L (341 μg/dL) are associated with poor neurological outcomes 2, 4

Diagnostic Considerations

• Suspect hyperammonemia in patients with unexplained neurological symptoms, respiratory alkalosis, ataxia, seizures, or coma 4, 1, 2, 4

Treatment Approaches

• Nitrogen scavenger medications may be used in the acute management of severe hyperammonemia 1

Hyperammonemia Causes and Clinical Recognition

Primary Causes: Urea Cycle Disorders

• Partial enzyme deficiencies can manifest later in childhood, adolescence, or even adulthood when triggered by metabolic stressors, typically presenting with severe hyperammonemia in the neonatal period 5

Clinical Recognition

• Early-onset (neonatal) presentations include lethargy, poor feeding, vomiting, hypotonia, seizures, and rapid progression to coma if untreated 5
• Late-onset presentations may include failure to thrive, irritability, ataxia, intellectual disabilities, and episodic encephalopathy triggered by illness or protein intake 5

Hyperammonemia Clinical Presentation and Diagnosis

Age-Dependent Presentation Patterns

• In neonates, the initial symptoms of hyperammonemia include lethargy, poor feeding, and vomiting, which typically appear within the first few days after feeding begins 6, 7
• These early symptoms in neonates precede the development of hypotonia and hyperventilation with respiratory alkalosis as ammonia levels continue to rise 6, 8
• If left unrecognized, neonates can progress to ataxia, disorientation, seizures, coma, and death 7
• In older patients with partial enzyme deficiencies, the earliest manifestations include failure to thrive, irritability, and episodic vomiting, often triggered by metabolic stressors such as illness or increased protein intake 7
• Older patients may also present with psychiatric manifestations including learning disabilities, delusion, and psychosis before overt neurological deterioration 8
• Confusion, lethargy, and dizziness represent early neurological symptoms in older patients 8
• Migraine-like headaches and low protein tolerance may be subtle early indicators in older patients 8

Critical Clinical Recognition Points

• The presence of respiratory alkalosis is an important early clue that distinguishes hyperammonemia from other causes of encephalopathy 6, 7

Pathophysiological Basis for Early Symptoms

• Ammonia crosses the blood-brain barrier and is metabolized to glutamine by astrocytes, causing increased extracellular potassium and intracellular osmolality 6, 7
• Lethargy and altered consciousness represent the earliest CNS manifestations before progression to structural brain damage with cerebral edema and inflammatory cytokine release 6, 8

Diagnostic Thresholds

• Hyperammonemia is defined as >100 µmol/L in neonates or ≥50 µmol/L in term infants, children, and adolescents 6, 7

Clinical Pitfalls to Avoid

• Do not wait for seizures, coma, or hypotonia to measure ammonia—these represent advanced manifestations, not early signs 6, 7

Hyperammonemia Diagnosis and Management

Adverse Prognostic Factors

• Hyperammonemic coma lasting more than 3 days, increased intracranial pressure, and plasma ammonia level greater than 1,000 μmol/l are associated with poor neurological outcomes, according to the Nature Reviews Nephrology 9
• The duration of coma inversely correlates with IQ at 12 months after recovery, as reported by the Nature Reviews Nephrology 9

Critical Clinical Pitfalls

• The prognosis of neurological damage is determined by the duration of hyperammonemic coma and plasma ammonia levels, with early management and reduced duration of hyperammonemic coma preventing adverse neurological outcomes, as stated by the Nature Reviews Nephrology 9
• The most important prognostic factor is the duration of hyperammonemic coma prior to the start of dialysis, not the rate of ammonia clearance, according to the Nature Reviews Nephrology 10

Monitoring Requirements

• Ammonia levels should be monitored every 3 hours during acute management, as recommended by the Nature Reviews Nephrology 9
• Blood samples for ammonia level analysis must be collected and processed according to specific guidelines to ensure accurate results, as specified by the Nature Reviews Nephrology 9

Management of Pediatric Hyperammonemia with Suspected Urea Cycle Defect

Immediate Initial Management

• For a pediatric patient with high ammonia levels and suspected urea cycle defect, immediately stop all protein intake, provide IV glucose and lipids to prevent catabolism, initiate nitrogen scavengers, and prepare for urgent hemodialysis given the persistently high ammonia level, according to the American Academy of Pediatrics and the European Society for Pediatric Nephrology 11, 12
• Maintain glucose infusion rate of 8-10 mg/kg/min to prevent catabolism and provide adequate calories 12
• Provide lipids starting at 0.5 g/kg/day, up to 3 g/kg/day to support nutrition and prevent catabolism 12
• Protein restriction must not exceed 48 hours to avoid triggering further catabolism, as recommended by the Society for Inherited Metabolic Disorders 11, 12

Pharmacological Nitrogen Scavenging

• Initiate IV sodium benzoate immediately as ammonia level exceeds the threshold for nitrogen scavenger therapy, according to the European Society for Pediatric Nephrology 11, 12
• Dosing for sodium benzoate: if body weight <20 kg, 250 mg/kg given over 90 minutes as bolus, then same dose as maintenance over 24 hours, as recommended by the American Academy of Pediatrics 12
• If body weight >20 kg, 5.5 g/m² given over 90 minutes as bolus, then same dose as maintenance over 24 hours, according to the Society for Inherited Metabolic Disorders 12

Critical Dialysis Decision

• At high ammonia levels with suspected UCD, prepare for urgent hemodialysis as this level meets criteria for dialysis consideration, especially if levels persist or rise despite medical therapy, according to the American Society of Nephrology and the European Renal Association 11, 12

Protein Reintroduction

• Reintroduce protein within 48 hours once ammonia decreases to a safe level to prevent catabolism from driving further ammonia production, as recommended by the Society for Inherited Metabolic Disorders and the European Society for Pediatric Nephrology 11, 12
• Start with 0.25 g/kg/day and gradually increase up to 1.5 g/kg/day, according to the American Academy of Pediatrics 12

Critical Pitfalls to Avoid

• Do not continue protein intake, as this directly contradicts the fundamental principle of reducing nitrogen load in acute hyperammonemia, according to the American Academy of Pediatrics and the European Society for Pediatric Nephrology 11, 12

Ammonia Production and Accumulation

Pathological Ammonia Accumulation

• Altered protein metabolism, particularly of branched-chain amino acids (BCAAs) that support glutamine synthesis and extrahepatic ammonia detoxification, can lead to accelerated protein breakdown and increased ammonia production, as noted by the American Association for the Study of Liver Diseases 13, 14
• Impaired hepatic ammonia clearance from loss of metabolic capacity combined with increased portosystemic shunting, which increases systemic ammonia concentration, is a key factor in the development of hyperammonemia, according to the American Association for the Study of Liver Diseases 13, 14

Diagnosis and Management of Hyperammonemia (Guideline‑Based)

Diagnostic Recommendations

• In patients with unexplained altered consciousness, obtain a plasma ammonia measurement; a normal result (≤ 35 µmol/L) makes hepatic encephalopathy unlikely and should prompt reconsideration of the diagnosis. French Hepatology Guidelines 2023 15
• When plasma ammonia exceeds 100 µmol/L together with a family or personal history of liver or neurological disease, mildly abnormal liver‑function tests, and severe neurological impairment, inherited metabolic disorders must be suspected. French Hepatology Guidelines 2023 15
• Accurate ammonia testing requires: fasting patient, avoidance of venous stasis, collection in an EDTA tube, immediate placement on ice, and transport to the laboratory at +4 °C within 60–90 minutes. French Hepatology Guidelines 2023 15

Clinical Implications

• The European Association for the Study of the Liver (EASL) states that a normal plasma ammonia level has a high negative predictive value for hepatic encephalopathy and should lead clinicians to question that diagnosis. EASL Guidelines 2022 16
• Plasma ammonia concentrations may remain elevated even after the clinical resolution of hepatic encephalopathy. EASL Guidelines 2022 16
• Hyperammonemia can be present in patients who do not exhibit hepatic encephalopathy and may occur even in the absence of overt liver disease. EASL Guidelines 2022 16

Guidelines for Ordering and Interpreting Serum Ammonia

1. Primary Clinical Indications – Patients With Known Liver Disease

• Order serum ammonia when a patient with cirrhosis experiences altered mental status for the first time to help distinguish hepatic encephalopathy from alternative causes such as alcohol withdrawal, structural brain injury, or medication effects. 17
• Order serum ammonia when a patient with established hepatic encephalopathy does not improve with standard therapy (e.g., lactulose or rifaximin). A normal ammonia level should trigger evaluation for other diagnoses including drug toxicity, infection, or intracranial pathology. 18
• A normal ammonia concentration (≤ 35 μmol/L) provides a high negative predictive value and should lead clinicians to reconsider hepatic encephalopathy as the primary diagnosis, redirecting work‑up toward other etiologies of altered mental status. 19

2. Primary Clinical Indications – Patients Without Known Liver Disease

• In neonates and young children presenting with lethargy, poor feeding, vomiting, or hypotonia within days of birth or after protein intake, obtain a serum ammonia measurement to promptly identify urea‑cycle disorders and prevent irreversible neurologic injury. 20

3. Situations in Which Serum Ammonia Should Not Be Ordered

• Do not routinely order ammonia in patients with cirrhosis who have typical, recurrent hepatic encephalopathy episodes with clear precipitating factors (e.g., infection, gastrointestinal bleeding, constipation). The clinical picture alone is sufficient for management. 17
• Do not use serial ammonia measurements to monitor response to hepatic encephalopathy treatment, because ammonia levels correlate poorly with clinical improvement and may remain elevated despite symptom resolution. 19

4. Critical Thresholds Requiring Urgent Intervention

• If serum ammonia exceeds 300 μmol/L in the setting of moderate‑to‑severe encephalopathy or seizures, initiate immediate ammonia‑scavenging therapy and prepare for urgent hemodialysis or continuous kidney replacement therapy. This threshold signals a high risk of rapid neurologic deterioration. 20

5. Interpretation and Management Pitfalls

• Ammonia concentrations alone should not dictate treatment intensity; clinical status (level of consciousness, presence of seizures, evidence of cerebral edema) must guide therapeutic decisions. Reliance on a single numeric value can lead to under‑ or overtreatment. 20
• In patients with cirrhosis and altered mental status, always search for precipitating factors (infection, bleeding, electrolyte disturbances, medication effects) regardless of the ammonia result, as these factors often require targeted interventions beyond ammonia‑lowering strategies. 19

Management of Asymptomatic Valproate‑Induced Hyperammonemia

Monitoring Protocol

• In patients receiving valproate who have an elevated serum ammonia level but no neurological symptoms, initiate close monitoring by repeating ammonia measurements every 3 hours during the initial assessment period. This approach allows early detection of worsening hyperammonemia before encephalopathy develops. 21